— Why it moved
Why PRFX Stock Gapped and Faded Today — May 29, 2026
A preclinical painkiller study gapped this 764K-share float from $1.37 to over $6 premarket — by the close it sat 38% below the alert.
What moved PRFX stock
PRF Technologies is the former PainReform, a rebranded shell that pivoted from pain drugs into "healthcare and AI-driven energy." The evening before, it reported that its PRF-110 post-surgical painkiller matched an approved benchmark with 72 hours of analgesic activity in a head-to-head preclinical study. Preclinical — in a company that had printed an all-time low of $1.28 eight days earlier.
The mechanics
764K shares in the float on a ~$2.6M cap: it takes very little buying to send that from $1.37 to over $6 before most people are awake, and very little selling to unwind it. Day volume ran about 75 times the float.
PRFX by the numbers
The alert window
Stock Pulse flagged it premarket at 7:08 AM at $4.84 — the $6.30 premarket high had already printed earlier. The post-alert peak was $5.39, four minutes into the regular session at 9:34 AM: 146 minutes after the alert for a best case of +11.4%. That is all a real-time reader ever had.
How PRFX's move ended
It chopped sideways for hours, the floor gave way around 2:30 PM, and it closed at $2.9999 — 38% below the alert and 44% off the peak. Best case +11%, actual close −38%; the fade was the whole story. Preclinical data from a rebranded shell is a study abstract, not efficacy in humans.
The tell: when a stock is already up 253% at the alert on overnight news, the remaining upside is measured in cents and the downside in halves.